MedTrace Logo

Intestinal Adsorbent and Breath Gas Levels

NCT04492839 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-27

No results posted yet for this study

Summary

To determine the effect of an intestinal adsorbent on hydrogen and methane breath levels in patients who have been on long term PPI therapy reporting reflux and abdominal symptoms at baseline.

Conditions

  • Gastroesophageal Reflux
  • Small Intestinal Bacterial Overgrowth

Interventions

DEVICE

Intestinal adsorbent

Participants will consume the 15ml of the intestinal adsorbent (3.5 g Silicon dioxide in 100 ml Silicic acid gel, Preservatives: Sorbic acid (E 200), Sodium benzoate (E 211). ) three times daily for 10 days. There are no known side effects of the medical device. The product is a class IIa medical device under the European council directive and the product will be used within it's current indications.

Sponsors & Collaborators

  • Dr Anthony Hobson

    lead OTHER

Principal Investigators

  • Anthony Hobson, PhD · Clinical Director

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-13
Primary Completion
2020-10-01
Completion
2020-12-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04492839 on ClinicalTrials.gov